WANG & LEE GROUP, Inc. (WLGS)

CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	3.95	6.83	4.17	4.14	4.07
Revenue Growth (YoY)	-42.11%	63.69%	0.84%	1.49%	-12.80%
Cost of Revenue	3.54	4.39	3.38	3.28	3.34
Gross Profit	0.41	2.44	0.79	0.86	0.74
Selling, General & Admin	2.96	3.21	1.43	1.22	0.59
Operating Expenses	2.96	3.21	1.43	1.22	0.59
Operating Income	-2.55	-0.77	-0.64	-0.36	0.14
Interest Expense	-0.13	-0.06	-0.04	-0.01	-0.05
Other Non Operating Income (Expenses)	0.13	0.18	0.08	0.02	0.19
Pretax Income	-2.54	-0.65	-0.6	-0.35	0.28
Income Tax Expense	-	-	-	-	0.01
Net Income	-2.54	-0.65	-0.6	-0.35	0.28
Net Income to Common	-2.54	-0.65	-0.6	-0.35	0.28
Net Income Growth	-	-	-	-	294.32%
Shares Outstanding (Basic)	15	14	12	12	12
Shares Outstanding (Diluted)	15	14	12	12	12
Shares Change (YoY)	6.27%	19.04%	-	-	-
EPS (Basic)	-0.17	-0.05	-0.05	-0.03	0.02
EPS (Diluted)	-0.17	-0.05	-0.05	-0.03	0.02
EPS Growth	-	-	-	-	294.35%
Free Cash Flow	-1.57	-3.81	-0.35	-0.48	-0.08
Free Cash Flow Per Share	-0.10	-0.27	-0.03	-0.04	-0.01
Gross Margin	10.43%	35.75%	18.84%	20.79%	18.04%
Operating Margin	-64.50%	-11.30%	-15.38%	-8.73%	3.50%
Profit Margin	-64.38%	-9.51%	-14.31%	-8.58%	6.82%
Free Cash Flow Margin	-39.73%	-55.88%	-8.46%	-11.68%	-1.90%
EBITDA	-2.53	-0.76	-0.64	-0.36	0.15
EBITDA Margin	-64.12%	-11.17%	-15.32%	-8.64%	3.65%
D&A For EBITDA	0.02	0.01	0	0	0.01
EBIT	-2.55	-0.77	-0.64	-0.36	0.14
EBIT Margin	-64.50%	-11.30%	-15.38%	-8.73%	3.50%
Effective Tax Rate	-	-	-	-	1.96%

Updated Dec 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q